Cancer Trials: Making the Most of Biomarkers

Biomarkers are becoming increasingly important in oncology clinical trials, as they offer a route to more effective (and cost-effective) targeted therapies. Precision’s David Parker, PhD discusses the evolving role of biomarkers in cancer drug development.

To read the full article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.